ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Olympus Opens New Global HQ for Therapeutic Solutions Division and U.S. Medical Business

TOKYO, Apr 8, 2021 - (ACN Newswire) - Olympus Corporation ("Olympus" - Director, Representative Executive Officer, President and CEO: Yasuo Takeuchi) announced today the opening of a new facility in Westborough, MA, to serve as the global headquarters for its Therapeutic Solutions Division (TSD) and its medical business in the United States.

Olympus has identified TSD as a strategic focus for growth and shifted its global head of TSD from Tokyo to the U.S. to have better access to a key medical industry cluster and generate growth through stronger business opportunities. Since the Transform Olympus initiatives were unveiled in 2019, many U.S.-based executives have been leading TSD growth; Olympus has dramatically expanded the business with acquisitions, as well as through organic growth.

The new 150,000-square-foot facility in Westborough will accommodate both the U.S. TSD employees and those formerly reporting to Image Stream Medical (ISM) facility located in Littleton, MA, with the exception of the manufacturing employees who will remain in Littleton. The facility will serve as one of several R&D hubs for Olympus, while enabling coordinated and agile management processes to support a global medical technology enterprise. At Olympus Westborough, the Olympus Continuum Training and Education Center will offer hands-on learning opportunities led by top medical experts using advanced medical equipment in a wetlab setting, both in person and virtually via the MedPresence telecollaboration platform. For interactions with customers and prospects, the Olympus OR Innovation Center showroom, also outfitted with the MedPresence platform, will provide an immersive environment for in-person or virtual integrated OR demonstrations.

The new Westborough facility will also provide enhanced opportunities for Olympus to build relationships with potential future employees. Olympus will facilitate relationships with potential job candidates, as well as continued partnerships with universities, colleges, and technical schools in the greater Boston area to bring world-class skills and capabilities to the company.

Nacho Abia, Chief Operating Officer of Olympus Corporation, said, "The U.S. market continues to be the largest in the world because of growing demand for minimally invasive treatment and surgery and the need for remote collaboration under COVID-19, so it's natural that we decided to combine all functions in Massachusetts in one place to facilitate agility and collaboration. This agile and globally-connected way of business will enhance our overall business competitiveness."

About Olympus' Medical business

As a leading medical technology company, our Medical business uses innovative capabilities in medical technology, therapeutic intervention, and precision manufacturing to help healthcare professionals deliver diagnostic, therapeutic, and minimally invasive procedures to improve clinical outcomes, reduce overall costs, and enhance the quality of life for patients and their safety. Olympus' Medical portfolio includes endoscopes, laparoscopes, and video imaging systems, as well as surgical energy devices, system integration solutions, medical services, and a wide range of endotherapy instruments for endoscopic and therapeutic applications. For more information, visit www.olympus-global.com.

For questions or additional information, please contact:

United States
Jennifer Bannan
+1 412-403-8742
jennifer.bannan@olympus.com

Europe, Middle East and Africa
Matthias Gengenbach
+49 15142369420
matthias.gengenbach@olympus-europa.com

Japan and APAC
Yuka Horimoto
+81-90-2490-1071
yuka.horimoto@olympus.com

Source: Olympus

Copyright 2021 ACN Newswire . All rights reserved.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.